Clinical outcomes of the vulnerable plaque sealing with drug-eluting stents for the treatment of intermedi-ate coronary stenosis
10.3969/j.issn.1006-5725.2017.17.018
- VernacularTitle:药物洗脱支架对冠状动脉临界病变合并易损斑块干预的临床预后
- Author:
Hanhua ZHU
1
;
Weide YANG
;
Ping ZHENG
;
Xiaoming HUANG
;
Guilin BU
;
Ying MIAO
;
Xiaoyan MA
;
Xiufeng LUO
;
Feng CHEN
;
Liwu TAN
Author Information
1. 541002,广西壮族自治区南溪山医院心内科
- Keywords:
drug-eluting stents;
intermediate coronary stenosis;
major adverse cardiovascular events;
vulnerable plaque
- From:
The Journal of Practical Medicine
2017;33(17):2877-2880
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the one-year clinical outcomes in patients with the vulnerable plaque sealing with drug-eluting stents for the treatment of intermediate coronary stenosis. Methods 327 patients with an-giographically intermediate lesions(diameter stenosis 50%~70%)with the vulnerable plaque which were detected by 64 slice coronary CT were prospectively enrolled. Patients were divided into medical therapy group (n = 160) and sirolimus-eluting stent group group(n=160). The incidences of one-year major adverse cardiovascular events (MACE)was evaluated(cardiac death,myocardial infarction ,revascularization). Results The MACE tended to be lower in the sirolimus-eluting stent group than medical therapy group(3.13%vs. 10%,log-rankχ2=6.62,P=0.01). The incident of cardiac death and myocardial infarction were lower in the sirolimus-eluting stent group than medical therapy group(1.25%vs. 5.63%,log-rankχ2=4.61,P=0.03). Conclusion The treatment of the siroli-mus-eluting stent can reduce MACE for the paitents with the vulnerable plaque of intermediate coronary stenosis than medical therapy only.
